Industry news that matters to you.  Learn more

Critical Diagnostics Inks Exclusive Worldwide License Agreement for New Heart Failure Biomarker sNEP

Critical Diagnostics recently announced that it has entered into a license agreement for the exclusive worldwide rights to the use of the biomarker soluble neprilysin (sNEP) in the diagnosis and monitoring of heart failure patients. Health Sciences Research Institute Germans Trias i Pujol Foundation (IGTP) of Barcelona Spain is the licensor.

Heart Failure Study Performed by Cleveland Clinic Shows Serial Testing with Cardiac Biomarker ST2 Predicts Outcomes of Hospitalized Patients

Critical Diagnostics recently reported that an abstract, “Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure,” presented at the American College of Cardiology Scientific Sessions in San Diego in March demonstrated in hospitalized heart failure patients that elevated levels of the cardiac biomarker ST2 were associated with an increased risk of adverse events. Authors include W.H. Wilson Tang of Cleveland Clinic, and Michael Felker and Christopher O’Connor of Duke University Medical Center and Duke Clinical Research Institute.

Opinions of 18 World-renowned Experts Contained in Consensus Paper on Role of Cardiac Biomarker ST2 in Heart Failure Care

Critical Diagnostics recently reported that The American Journal of Cardiology released an online version of a comprehensive consensus paper discussing the evidence base behind the evolving role of the cardiac biomarker ST2 and its appropriate uses in the management of patients with heart failure and related cardiac diseases.

Critical Diagnostics Launches Rapid Test for Managing Heart Failure Patients

Critical Diagnostics recently announced that it has expanded its cardiac biomarker testing product portfolio by CE marking the Aspect-PLUS™ ST2 test, the world’s first and only rapid quantitative ST2 test. Results are reported in under 30 minutes.

Updated CME Program Is Designed To Help Clinicians Reduce Heart Failure Patient Hospital Readmissions

Critical Diagnostics recently announced that an updated accredited, self-learning program entitled, “Reducing Heart Failure Readmissions: Case Studies Utilizing Biomarkers for Risk Stratification,” is available now online at www.heartfailurecases.com.